This metabolic adaptability of tumors explains the current outcomes of single‐targeted GLS1 inhibition in pancreatic cancer and justifies the need for a more strategic approach, specifically by the combination of GLS1 and GTK inhibition, aiming at both main and adaptive metabolic networks. This evidence concerns the gene GLS and pancreatic neoplasm.